目的:探讨重组人血小板生成素(rhTPO)联合标准剂量糖皮质激素在治疗成人原发免疫性血小板减少症(ITP)方面的短期疗效及安全性。方法:选取2018年1月1日至2024年6月1期间北华大学附属医院血液科收治的93例ITP患者进行回顾性分析,根据治疗方法的不同,将患者分为研究组(46例)和对照组(47例),对照组患者给予标准剂量醋酸泼尼松片治疗,研究组患者在标准剂量醋酸泼尼松片基础上联合重组人血小板生成素治疗,比较两组患者治疗前及治疗后第3、7、14 d时PLT水平的变化情况、PLT增幅情况以及总有效率,观察药物的不良反应。结果:研究组与对照组治疗后的PLT与治疗前相比较,均高于治疗前水平,研究组在治疗后d14,PLT数值、较用药前PLT升高程度均显著高于对照组(P 0.05)。结论:重组人血小板生成素联合标准剂量糖皮质激素治疗原发免疫性血小板减少症的短期疗效较显著,可明显升高PLT计数,且安全性较好,不会出现严重的不良反应。Objective: Investigate the short-term therapeutic effect and safety of recombinant human thrombopoietin (rhTPO) in conjunction with standard-dose glucocorticoids for the treatment of adult primary immune thrombocytopenia (ITP). Method: A retrospective analysis was performed on 93 patients with immune thrombocytopenia (ITP) admitted to the Hematology Department of Affiliated Hospital of Beihua University from January 1, 2018 to June 1, 2024. They were separated into a study group with 46 cases and a control group containing 47 cases. Patients in the control group were given standard-dose prednisone acetate tablets, while patients in the study group were treated with recombinant human thrombopoietin in addition to standard-dose prednisone acetate tablets. The changes in platelet count (PLT) levels before treatment and on the 3rd, 7th, and 14th days after treatment, as well as platelet increase and total effective rate, were compared between the two groups. A
目的:运用网状Meta分析的方法评估中成药联合糖皮质激素(glucocorticoid, GC)治疗原发性肾病综合征(primary nephrotic syndrome, PNS)的疗效。方法:检索中成药联合GC治疗PNS的随机对照试验。在筛选文献、提取资料和评价偏倚风险后,对所纳入的指标进行网状Meta分析。结果:共纳入31篇文献,2275例PNS患者。结果显示,在提高总有效率、降低24 h尿蛋白定量方面,5种中成药联合GC治疗成人PNS优于单纯GC治疗。概率排序显示,在提高总有效率方面,昆仙胶囊排第一位;在升高血浆白蛋白方面,雷公藤制剂排第一位;在降低尿素氮方面,黄葵胶囊排第一位。结论:中成药联合GC的方案可提高PNS的治疗效果。Objective: To evaluate the efficacy of different Chinese patent medicines combined with glucocorticoid in treatment of primary nephrotic syndrome (PNS) by Network Meta analysis. Methods: Randomized controlled trial of Chinese patent medicine combined with glucocorticoid in treatment of PNS was retrieved. After screening the literature, extracting data and evaluating bias risk, the included indicators were analyzed by Network Meta analysis. Results: A total of 31 articles were included, involving 2275 patients with PNS. The results showed that in terms of improving the total effective rate and reducing 24-hour urinary protein, five kinds of Chinese patent medicines combined with glucocorticoid were better than glucocorticoid alone in the treatment of adult PNS. SUCRA showed that in terms of improving the total effective rate, Kunxian capsule ranks first;in terms of increasing the level of albumin, Tripterygium pharmaceutical preparation ranks first;in terms of reducing urea nitrogen, Huangkui Capsule ranks first. Conclusion: Chinese patent medicine combined with glucocorticoid can improve the therapeutic effect of PNS.
